Bayer AG (BAYRY) to Post FY2022 Earnings of $2.94 Per Share, Jefferies Group Forecasts

Bayer AG (OTCMKTS:BAYRY) – Equities researchers at Jefferies Group issued their FY2022 earnings per share estimates for shares of Bayer in a note issued to investors on Tuesday. Jefferies Group analyst J. Holford expects that the company will post earnings per share of $2.94 for the year.

Bayer (OTCMKTS:BAYRY) last issued its quarterly earnings data on Thursday, October 26th. The company reported $0.43 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.29 by $0.14. Bayer had a return on equity of 18.53% and a net margin of 10.88%.

Several other analysts have also commented on BAYRY. ValuEngine lowered Bayer from a “buy” rating to a “hold” rating in a report on Friday, September 22nd. BNP Paribas upgraded Bayer from a “neutral” rating to an “outperform” rating in a research report on Monday, September 25th. Finally, Zacks Investment Research downgraded Bayer from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 31st. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $36.00.

Shares of Bayer (BAYRY) traded up $0.23 on Wednesday, hitting $32.05. The company had a trading volume of 577,546 shares, compared to its average volume of 433,149. The company has a quick ratio of 1.01, a current ratio of 1.51 and a debt-to-equity ratio of 0.67. Bayer has a one year low of $26.98 and a one year high of $35.41. The company has a market capitalization of $104,700.00, a price-to-earnings ratio of 28.11, a P/E/G ratio of 1.82 and a beta of 1.14.

WARNING: This story was first published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The original version of this story can be accessed at

Bayer Company Profile

Bayer AG is a life science company. The Company’s segments are Pharmaceuticals, Consumer Health, Animal Health and Covestro. The Pharmaceuticals segment focuses on prescription products, especially for cardiology and women’s healthcare, and on specialty therapeutics in the areas of oncology, hematology and ophthalmology.

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply